- Home
- IKNA vs MCRB Comparison
IKNA vs MCRB Comparison
Compare IKNA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- MCRB
- Stock Information
- Founded
- IKNA 2016
- MCRB 2010
- Country
- IKNA United States
- MCRB United States
- Employees
- IKNA N/A
- MCRB N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- MCRB Health Care
- Exchange
- IKNA Nasdaq
- MCRB Nasdaq
- Market Cap
- IKNA 61.8M
- MCRB 72.0M
- IPO Year
- IKNA 2021
- MCRB 2015
- Fundamental
- Price
- IKNA $1.36
- MCRB $7.63
- Analyst Decision
- IKNA Strong Buy
- MCRB Hold
- Analyst Count
- IKNA 1
- MCRB 4
- Target Price
- IKNA $4.00
- MCRB $73.67
- AVG Volume (30 Days)
- IKNA 95.6K
- MCRB 75.0K
- Earning Date
- IKNA 08-07-2025
- MCRB 08-12-2025
- Dividend Yield
- IKNA N/A
- MCRB N/A
- EPS Growth
- IKNA N/A
- MCRB N/A
- EPS
- IKNA N/A
- MCRB 8.98
- Revenue
- IKNA N/A
- MCRB N/A
- Revenue This Year
- IKNA N/A
- MCRB N/A
- Revenue Next Year
- IKNA N/A
- MCRB N/A
- P/E Ratio
- IKNA N/A
- MCRB $0.89
- Revenue Growth
- IKNA N/A
- MCRB N/A
- 52 Week Low
- IKNA $0.97
- MCRB $6.53
- 52 Week High
- IKNA $1.94
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- IKNA 56.43
- MCRB 48.66
- Support Level
- IKNA $1.10
- MCRB $7.25
- Resistance Level
- IKNA $1.46
- MCRB $7.89
- Average True Range (ATR)
- IKNA 0.07
- MCRB 0.46
- MACD
- IKNA -0.00
- MCRB 0.11
- Stochastic Oscillator
- IKNA 57.58
- MCRB 60.23
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.